CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells

International Journal of Cancer

Volumn 126, Issue 4, 2010, Pages 864-875

  Chao, Celia ^a,b   Han, Xueliang ^a   Ives, Kirk ^a   Park, Jeseong ^a,b   Kolokoltsov, Andrey A ^a   Davey, Robert A ^a   Moyer, Mary P ^c   Hellmich, Mark R ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c NONE   (United States)

Author keywords

CCK2 receptors; Colorectal tumorigenesis; Gastrin; NCM356 cells

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; COMPLEMENTARY DNA; GASTRIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; RETROVIRUS VECTOR; CALCIUM; PRIMER DNA;

ARTICLE; CELL GROWTH; COLON MUCOSA; COLON TUMOR; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOMA; ANIMAL; CANCER STAGING; CARCINOMA; CELL DIVISION; COLON; COLORECTAL TUMOR; CULTURE TECHNIQUE; DISEASE COURSE; GENETIC VARIABILITY; GENETICS; INTESTINE MUCOSA; METABOLISM; METHODOLOGY; MOUSE; MUTATION; PATHOLOGY; PHYSIOLOGY; SECRETION;

ADENOMA; ANIMALS; CALCIUM; CARCINOMA; CELL CULTURE TECHNIQUES; CELL DIVISION; COLON; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA PRIMERS; GASTRINS; GENETIC VARIATION; HUMANS; INTESTINAL MUCOSA; MICE; MUTATION; NEOPLASM STAGING; RECEPTOR, CHOLECYSTOKININ B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 74049157658     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24845     Document Type: Article

References (39)

1. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87: 159-70.
2. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001;1: 55-67.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
4. Hellmich MR, Rui XL, Hellmich HL, Fleming RY, Evers BM, Townsend CM, Jr. Human colorectal cancers express a constitutively active cholecystokinin-B/ gastrin receptor that stimulates cell growth. J Biol Chem 2000;275:32122-8.
5. Smith AM, Watson SA. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. Gut 2000;47:820-4.
6. Watson SA, Morris TM, McWilliams DF, Harris J, Evans S, Smith A, Clarke PA. Potential role of endocrine gastrin in the colonic adenoma carcinoma sequence. Br J Cancer 2002;87:567-73.
7. Aly A, Shulkes A, Baldwin GS. Gastrins, cholecystokinins and gastrointestinal cancer. Biochim Biophys Acta 2004;1704: 1-10.
8. Renga M, Brandi G, Paganelli GM, Calabrese C, Papa S, Tosti A, Tomassetti P, Miglioli M, Biasco G. Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia. Gut 1997; 41:330-2.
9. Sobhani I, Lehy T, Laurent-Puig P, Cadiot G, Ruszniewski P, Mignon M. Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology 1993;105: 22-30.
10. Breuer-Katschinski B, Nemes K, Marr A, Rump B, Leiendecker B, Breuer N, Goebell H. Helicobacter pylori and the risk of colonic adenomas. Colorectal Adenoma Study Group. Digestion 1999;60:210-15.
11. Talley NJ, Chute CG, Larson DE, Epstein R, Lydick EG, Melton LJ, III. Risk for colorectal adenocarcinoma in pernicious anemia. A population-based cohort study. Ann Intern Med 1989;111:738-42.
12. Thorburn CM, Friedman GD, Dickinson CJ, Vogelman JH, Orentreich N, Parsonnet J. Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998; 115:275-80.
13. Koh TJ, Bulitta CJ, Fleming JV, Dockray GJ, Varro A, Wang TC. Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 2000;106:533-9.
14. Watson SA, Smith AM. Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis. Cancer Res 2001; 61:625-31.
15. Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M, Roques BP. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999;51:745-81.
16. Dockray GJ, Varro A, Dimaline R, Wang T. The gastrins: their production and biological activities. Annu Rev Physiol 2001; 63:119-39.
17. Singh P. Role of Annexin-II in GI cancers: interaction with gastrins/progastrins. Cancer Lett 2007;252:19-35.
18. Jin G, Dubeykovskiy AN, Pritchard DM, Betz KS, Varro A, Wang TC. Inactivation of cholecystokinin-2 receptor inhibits progastrin-dependent colonic proliferation and colorectal cancer in mice. Gastroenterology 2008;134:A115.
19. Stauffer JS, Manzano LA, Balch GC, Merriman RL, Tanzer LR, Moyer MP. Development and characterization of normal colonic epithelial cell lines derived from normal mucosa of patients with colon cancer. Am J Surg 1995;169:190-5.
20. Kolokoltsov AA, Weaver SC, Davey RA. Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins. J Virol 2005;79:756-63.
21. Hellmich MR, Battey JF, Northup JK. Selective reconstitution of gastrin-releasing peptide receptor with G alpha q. Proc Natl Acad Sci U S A 1997;94:751-6.
22. Chao C, Goluszko E, Lee YT, Kolokoltsov AA, Davey RA, Uchida T, Townsend CM, Jr, Hellmich MR. Constitutively active CCK2 receptor splice variant increases Srcdependent HIF-1 alpha expression and tumor growth. Oncogene 2007;26:1013-19.
23. Chao C, Ives KL, Goluszko E, Kolokoltsov AA, Davey RA, Townsend CM, Jr, Hellmich MR. SRC regulates constitutive internalization and rapid resensitization of a cholecystokinin 2 receptor splice variant. J Biol Chem 2005;280:33368-73.
24. Cheng ZJ, Harikumar KG, Ding WQ, Holicky EL, Miller LJ. Analysis of the cellular and molecular mechanisms of trophic action of a misspliced form of the type B cholecystokinin receptor present in colon and pancreatic cancer. Cancer Lett 2005;222:95-105.
25. Hellmich MR, Hull R, Harper EA. Structure/function of the CCK2/gastrin receptor. In: Merchant JL, eds. Gastrin in the New Millenniumed. Belleville: MedPub Inc., 2004. 71-92.
26. Todisco A, Takeuchi Y, Urumov A, Yamada J, Stepan VM, Yamada T. Molecular mechanisms for the growth factor action of gastrin. Am J Physiol 1997; 273:G891-G898.
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
28. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;9:517-31.
29. Chao C, Tallman ML, Ives KL, Townsend CM, Jr, Hellmich MR. Gastrointestinal hormone receptors in primary human colorectal carcinomas. J Surg Res 2005;129: 313-21.
30. Reubi JC, Waser B, Schmassmann A, Laissue JA. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located? Int J Cancer 1999;81: 376-86.
31. Dehez S, Daulhac L, Kowalski-Chauvel A, Fourmy D, Pradayrol L, Seva C. Gastrininduced DNA synthesis requires p38-MAPK activation via PKC/Ca(2+) and Src-dependent mechanisms. FEBS Lett 2001;496:25-30.
32. Guo YS, Cheng JZ, Jin GF, Gutkind JS, Hellmich MR, Townsend CM, Jr. Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways. Evidence for involvement of ERK5 kinase and transactivation of the epidermal growth factor receptor. J Biol Chem 2002;277: 48755-63.
33. Hocker M. Molecular mechanisms of gastrin-dependent gene regulation. Ann N Y Acad Sci 2004;1014:97-109.
34. Noble PJ, Wilde G, White MR, Pennington SR, Dockray GJ, Varro A. Stimulation of gastrin-CCKB receptor promotes migration of gastric AGS cells via multiple paracrine pathways. Am J Physiol Gastrointest Liver Physiol 2003;284:G75-G84.
35. Stepan VM, Dickinson CJ, del Valle J, Matsushima M, Todisco A. Cell typespecific requirement of the MAPK pathway for the growth factor action of gastrin. Am J Physiol 1999;276: G1363-G1372.
36. Smith AM, Justin T, Michaeli D, Watson SA. Phase I/II study of G17-DT, an antigastrin immunogen, in advanced colorectal cancer. Clin Cancer Res 2000;6:4719-24.
37. Berna MJ, Tapia JA, Sancho V, Jensen RT. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr Opin Pharmacol 2007;7:583-92.
38. Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, Harrison P, Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, et al. Gastrazole (JB95008), a novel CCK2/ gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: resultsfrom two randomised controlled trials. Br J Cancer 2006;94: 1107-15.
39. Sanghi S, MacLaughlin EJ, Jewell CW, Chaffer S, Naus PJ, Watson LE, Dostal DE. Cyclooxygenase-2 inhibitors: a painful lesson. Cardiovasc Hematol Disord Drug Targets 2006;6:85-100.